Results 121 to 130 of about 13,218 (206)

Reversible Effects of Integrase Inhibitors on Newly Differentiated Adipocytes. [PDF]

Viruses
Pickering RT, Asundi A, Olson A, Soden K, Lin NH.   +4 more
europepmc   +1 more source

Exploring the impact of baseline and on-treatment variables on durability of responses to fostemsavir through weeks 96 and 192 in the phase 3 BRIGHTE study. [PDF]

HIV Med
Gartland M, Wang X, Liao Q, Li B, Du F, Krystal M, Tenorio AR, Pierce A, Castillo-Mancilla JR.   +8 more
europepmc   +1 more source

Advancements in development of novel class of HIV protease inhibitors. [PDF]

Ann Med
Gu WG, Yin GZ, Zhang YP.
europepmc   +1 more source

Cardiometabolic impact of dolutegravir as second-line therapy: secondary analysis of a randomized controlled trial. [PDF]

AIDS
Nyein PP, Donoghoe MW, Eriobu N, Uche B, Kaplan R, Carey D, Brown D, Kundro M, Dharan NJ, Hanson J, Petoumenos K, Matthews GV, the D EFT study group.   +12 more
europepmc   +1 more source

A Randomized Trial to Compare Dolutegravir Plus Boosted Darunavir Versus Recommended Standard of Care Antiretroviral Regimens in People With HIV-1, Whose First-line Non-nucleoside Reverse Transcriptase Inhibitor Therapy Has Failed: Final 96-week Results of the D2EFT Study. [PDF]

Clin Infect Dis
Nyein PP, Borok M, Eriobu N, Kaplan R, Kumarasamy N, Avihingsanon A, Losso MH, Azwa I, Karyana M, Dao S, Cisse M, Andrade Villanueva JF, Lupo S, Cardoso SW, Yunihastuti E, Subronto YW, Fitriah M, Katu S, Brown D, Papot E, Hutchinson J, Kelleher A, Hanson J, Dharan NJ, Petoumenos K, Matthews GV, D2EFT Study Team.   +26 more
europepmc   +1 more source

Repurposing HIV Protease Inhibitors against West Nile Virus: Insights from Molecular Docking and Molecular Dynamics Simulations. [PDF]

ACS Phys Chem Au
Dos Santos RD, Colherinhas G, Cardoso WB.   +2 more
europepmc   +1 more source

Similar Efficacy, Safety, and Immune Improvement Through 96 Weeks in Individuals With Limited HIV-1 Treatment Options Using Twice-Daily Dolutegravir- or Fostemsavir-based Regimens. [PDF]

Open Forum Infect Dis
Castagna A, Marcon I, Du F, Li B, Wang M, Clark A, Donovan C, Jones B, Prakash M.   +8 more
europepmc   +1 more source

Determinants of Metabolic Syndrome in Virally Suppressed People Living with HIV: A Single-Center Comparative Analysis of Antiretroviral Regimens. [PDF]

Metabolites
Biały M, Inglot M.
europepmc   +1 more source

Maintain, not obtain: rethinking HIV care in sub-Saharan Africa in the era of dolutegravir. [PDF]

Front Public Health
Perno CF, Orlando S, Majid NA, Sangare H, Luanga R, Roccucci M, Silaghi LA, Sidumo Z, Brambilla D, Ceffa S, Guidotti G, Ciccacci F.   +11 more
europepmc   +1 more source